The Role of Glutamate Signaling in Pain Processes and its Regulation by GCP II Inhibition
This chapter will review, in general terms, the current knowledge of glutamate and its effects at various glutamate receptors with regards to nociception. In addition, we will briefly review the glutamatergic drugs currently in use as treatments for pain, as well as known novel candidates in various stages of clinical trial. Lastly, we will summarize the data supporting a novel target for pain intervention by way of GCPII inhibition, which appears devoid of the side-effects associated with direct glutamate receptor antagonists and thus holds major promise for future therapy. GCPII (glutamate carboxypeptidase II) cleaves the prevalent neuropeptide NAAG into NAA and glutamate and there is widespread evidence and belief that targeting the glutamate derived from this enzymatic action may be a promising therapeutic route.
Keywords: Central nervous system; GCPIII; Glutamate carboxypeptidase II (GCPII); Homologs; NAAG; NAALADase L; PSMA; PSMAL; Splice variants; biological role; cancer metastasis; dorsal horn; glutamate receptors; homologs; neuropathy; pain; peripheral nervous system
Document Type: Research Article
Publication date: 2012-03-01
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.